“Paper NDAs”
This article was originally published in The Tan Sheet
Executive Summary
Pursuing Rx-to-OTC switches under section 505(b)(2) of Hatch/Waxman patent law is "potentially a very good avenue" for companies to use, Morgan Lewis lawyer Stephen Paul Mahinka says at Regulatory Affairs Professionals Society annual conference in Washington, D.C. Oct. 9. Both Wyeth and McNeil used 505(b)(2) application, or "paper NDA," approach to seek OTC approval for loratadine (Schering-Plough's Claritin) (1"The Tan Sheet" Feb. 4, 2002, p. 3). Mahinka expects "some response" from FDA in next several months on citizen petition filed by Pfizer and Pharmacia in 2001 requesting FDA disallow 505(b)(2) NDAs from relying on innovator's data...
You may also be interested in...
Claritin Patent Infringement Suit Brings Industry Into OTC Antihistamine Fray
Schering-Plough's lawsuits against McNeil Consumer Healthcare and Whitehall-Robins could at least temporarily relieve FDA of having to make a highly charged public policy decision on whether to advocate a forced switch of second-generation antihistamines
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.